- Home
- DOCN vs SRRK Comparison
DOCN vs SRRK Comparison
Compare DOCN & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOCN
- SRRK
- Stock Information
- Founded
- DOCN 2011
- SRRK 2012
- Country
- DOCN United States
- SRRK United States
- Employees
- DOCN N/A
- SRRK N/A
- Industry
- DOCN Retail: Computer Software & Peripheral Equipment
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DOCN Technology
- SRRK Health Care
- Exchange
- DOCN Nasdaq
- SRRK Nasdaq
- Market Cap
- DOCN 3.5B
- SRRK 4.2B
- IPO Year
- DOCN 2021
- SRRK 2018
- Fundamental
- Price
- DOCN $35.74
- SRRK $44.78
- Analyst Decision
- DOCN Buy
- SRRK Strong Buy
- Analyst Count
- DOCN 10
- SRRK 7
- Target Price
- DOCN $42.11
- SRRK $40.43
- AVG Volume (30 Days)
- DOCN 788.7K
- SRRK 1.3M
- Earning Date
- DOCN 11-04-2024
- SRRK 11-12-2024
- Dividend Yield
- DOCN N/A
- SRRK N/A
- EPS Growth
- DOCN N/A
- SRRK N/A
- EPS
- DOCN 0.87
- SRRK N/A
- Revenue
- DOCN $756,564,000.00
- SRRK N/A
- Revenue This Year
- DOCN $14.25
- SRRK N/A
- Revenue Next Year
- DOCN $13.03
- SRRK N/A
- P/E Ratio
- DOCN $40.86
- SRRK N/A
- Revenue Growth
- DOCN 12.08
- SRRK N/A
- 52 Week Low
- DOCN $26.63
- SRRK $6.76
- 52 Week High
- DOCN $44.80
- SRRK $46.19
- Technical
- Relative Strength Index (RSI)
- DOCN 38.85
- SRRK 67.23
- Support Level
- DOCN $37.97
- SRRK $40.22
- Resistance Level
- DOCN $39.50
- SRRK $44.22
- Average True Range (ATR)
- DOCN 1.57
- SRRK 2.80
- MACD
- DOCN -0.36
- SRRK -0.30
- Stochastic Oscillator
- DOCN 17.58
- SRRK 84.04
About DOCN DigitalOcean Holdings Inc.
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and Other countries.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.